Traders should watch Q3 trends for margin recovery as EBITDA guidance was trimmed despite the revenue raise. The growing contribution from less capital-intensive service lines is positive for cash flow, but cost growth (SG&A up 29% YoY) bears monitoring. Continued share repurchases and debt reduction support downside support.
Price Chart
Executive Summary
Viemed Healthcare reported Q2 2026 record revenue of $78.1M (+23.9% YoY), driven by strong ventilator, PAP, and sleep resupply patient growth. However, GAAP diluted EPS fell to $0.07 (from $0.08 YoY) and Adjusted EBITDA declined 4% to $13.7M, partly due to a non-recurring gain in the prior year. FY2026 revenue guidance was narrowed up (low end raised to $314M) while Adjusted EBITDA guidance was lowered to $64-68M, creating a mixed picture of top-line momentum offset by margin pressure.
Key Financial Metrics
Key Facts
- Record Q2 revenue of $78.1M, up 23.9% YoY and 3.6% sequentially
- Record ventilator patient count of 12,635, up 4.0% YoY and 4.5% sequentially
- GAAP diluted EPS $0.07, down from $0.08 in Q2 2025 (-12.5% YoY)
- Adjusted EBITDA $13.7M, down 4.0% YoY; prior year included $1.0M non-recurring gain
- FY2026 revenue guidance raised low-end to $314M-$320M (from $312M-$320M)
- FY2026 Adjusted EBITDA guidance lowered to $64M-$68M (from $65M-$69M)
- Repurchased 530,802 shares for $5.1M in Q2; debt reduced to $6.4M with $46M available on credit lines
- Free cash flow of $8.6M in Q2 and $34.4M trailing twelve months
Financial Impact
Revenue growth of 23.9% to $78.1M vs $63.1M YoY; GAAP net income declined to $2.8M from $3.2M
Risk Factors
- Adjusted EBITDA guidance lowered despite revenue raise, signaling margin compression
- SG&A expense grew 29% YoY, outpacing revenue growth of 23.9%
- Dependence on Medicare/Medicaid reimbursement (~70% of mix) exposes to regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001729149-26-000041 |
| Document: vmd-20260803.htm | 0001729149-26-000041 |
| Document: viemed_q22026supplementa.htm | 0001729149-26-000041 |
| Document: 0001729149-26-000041-index-headers.html | 0001729149-26-000041 |
| Document: 0001729149-26-000041-index.html | 0001729149-26-000041 |
| Document: 0001729149-26-000041.txt | 0001729149-26-000041 |
| 8-K Data (Synthetic) | 0001729149-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 24, 2026 4w ago | SC 13D/A | $8.91 $9.11 | ▼ −2.24% | ▼ −2.99% | $9.73 (−9.20%) |
Aug 20, 2026 9w ago | 8-K | $8.85 $9.09 | ▲ +2.71% | ▲ +3.01% | $9.73 (+9.94%) |
Aug 3, 2026 12w ago | 8-K | $9.84 $9.82 | ▼ −0.15% | ▲ +0.05% | $9.73 (−1.07%) |
Jun 4, 2026 20w ago | 8-K | $9.97 $9.92 | ▼ −0.50% | ▼ −0.73% | $9.73 (−2.41%) |
Jun 2, 2026 20w ago | 8-K | $9.56 $9.84 | ▲ +2.93% | ▲ +2.53% | $9.73 (+1.78%) |
May 5, 2026 24w ago | 8-K | $8.52 $8.52 | · 0.00% | ▲ +0.33% | $9.73 (+14.27%) |
Mar 4, 2026 33w ago | 8-K | $8.40 $8.78 | ▲ +4.52% | ▲ +5.84% | $9.73 (+15.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers